Related Experiment Videos
A novel behavioral paradigm for assessing tinnitus using schedule-induced polydipsia avoidance conditioning (SIP-AC)
Edward Lobarinas1, Wei Sun, Ross Cushing
1Center for Hearing and Deafness, Hearing Research Lab, University of Buffalo, 215 Parker Hall, Buffalo, NY 14214, USA. el24@buffalo.edu
Hearing Research
|March 31, 2004
Summary
A new method accurately measures tinnitus onset and recovery in rats using a licking behavior task. Salicylate administration induced tinnitus-like behavior, which resolved over days, validating this approach for tinnitus research.
Area of Science:
- Neuroscience
- Behavioral Science
- Pharmacology
Background:
- Tinnitus, a phantom auditory perception, significantly impacts quality of life.
- Measuring tinnitus onset and recovery in animal models is crucial for understanding its mechanisms and developing treatments.
Purpose of the Study:
- To develop and validate a behavioral technique for quantifying tinnitus-like behavior in rats.
- To assess the effects of salicylate, a known tinnitus-inducing agent, on this behavioral measure.
Main Methods:
- Rats were trained using schedule-induced polydipsia (SIP) and a go/no-go task with auditory stimuli and foot shock.
- Tinnitus was induced using intraperitoneal injections of salicylate at doses of 50, 100, 150, and 350 mg/kg.
- Behavioral responses (licks-in-quiet and licks-in-sound) were monitored before, during, and after salicylate treatment.
Main Results:
- Salicylate doses of 150 and 350 mg/kg significantly reduced licks-in-quiet, indicating tinnitus-like behavior.
- Audibility of auditory stimuli was maintained across all salicylate doses.
- Tinnitus-like behavior gradually recovered within 2-3 days after high-dose salicylate administration.
Conclusions:
- The developed behavioral technique reliably measures the onset and recovery of tinnitus-like behavior in rats.
- This method provides a valuable tool for investigating the neural mechanisms underlying tinnitus.
- The findings support the use of this model for preclinical assessment of anti-tinnitus therapies.